Sentences with phrase «cancer after a transplant»

The findings, published online Nov. 13 in Science Translational Medicine, could pave the way for improvements in preventing GVHD and rejection of transplanted bone marrow and new therapies to prevent or treat a relapse of the underlying cancer after a transplant.

Not exact matches

In the early 2000s, Johns Hopkins scientists Leo Luznik and Ephraim Fuchs found that giving patients high doses of cyclophosphamide — a drug derived from nitrogen mustard and used to treat blood cancers — three days after bone marrow transplant successfully thwarts acute and chronic GVHD.

Researchers at Dana - Farber / Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only.

Johns Hopkins Kimmel Cancer Center scientists first used cyclophosphamide to prevent severe graft - versus - host disease (GVHD) after bone marrow transplant involving haploidentical or «half - matched» transplants, a treatment first used in 2000 at the Cancer Center to treat leukemias and other blood cancers.

If the retroviruses infected a person during or after a transplant, they could disrupt important human genes, leading to cancer or other diseases.

In a world first, Ouarda Touirat, a 32 - year - old cancer survivor in Belgium, delivered a healthy baby this year after undergoing an ovarian tissue transplant.

Experience with lymphoma patients, who receive a transplant of their own blood or bone cells after radiation to wipe out their cancer, has shown «there's no doubt it helps,» says bone marrow transplant expert Nelson Chao of Duke University in Durham, North Carolina.

Monitoring immune cell activity — including phenotyping immune cell subsets, tracking cell proliferation, and measuring cytokine production — can provide insights into the overall status of immune function in patients, particularly those undergoing immunosuppression after transplants, enduring cancer treatment, or suffering from autoimmune disease or other pathologies that affect the immune system.

«Preventing graft - versus - host disease and relapse after transplant requires a difficult balance of eliminating the bad, overactive effector T cells, without suppressing the good, regulatory T cells,» said Kean, who is also an associate professor of pediatrics at the University of Washington School of Medicine and a member of the Fred Hutchinson Cancer Research Center.

A decade ago, the medical world was shocked when a patient in Berlin, Germany, had been declared free of HIV after receiving a stem cell transplant to treat cancer.

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

After receiving a transplant of ovarian cancer cells, mice were restrained to cause stress.

After cancer chemotherapy failed, Brown needed a stem cell transplant for his leukemia.

He began to show immediate improvement and after three cycles of treatment received a blood stem cell transplant, and since has been cancer free for 19 months.

«The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants.

The researchers studied 24 tumor samples from breast cancer patients after the samples were transplanted into mice.

After infection, some healthy people experience a month or more of flu - like symptoms, but the disease can cause seizures and potentially fatal encephalitis in the immunocompromised, including patients receiving transplants, those with HIV / AIDS, cancer patients, the elderly, and young children.

Published by Noha Sharafeldin, M.D., M.Sc., Ph.D., instructor in UAB's Institute for Cancer Outcomes and Survivorship and Division of Hematology and Oncology, this study helps add a missing piece to a long - unsolved puzzle about post-transplant effects on recipients, specifically that vulnerable subpopulations of similar transplants can benefit from targeted interventions in the years after they receive their lifesaving treatment.

Hear stories from patients who have recovered from leukemia and other blood cancers thanks to stem cell transplants; the donors who provided stem cells to loved ones; and the medical staff that cared for them before, during, and after the procedure.

After the cancellation of Dallas in 1991, Hagman was forced to slow down his busy schedule due to an ongoing battle with liver cancer, and in August of 1995 he was the recipient of a liver transplant, a procedure that saved his life.

Other similar powerful medications used to disable the immune system after organ transplants or cancer have also been used.